Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
ID: RFA-TR-23-018Type: BOTH
Overview

Topic

Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: STTRPhase: BOTHYear: 2024

Topic Link

https://www.sbir.gov/node/2486915

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through a Small Business Technology Transfer (STTR) program. The goal of this funding opportunity is to support the development of bench top, portable, automated, self-contained systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be able to automate tissue preculture and loading, system operation, perfusion systems, and cell culture conditions. It should also include in-line sensors for monitoring and sensing, as well as software for instrument control and data processing. The system should be cost-effective, mass producible, and robust. The performance of the system should be characterized and validated, and the applicant should propose quantitative metrics for evaluating progress. The long-term goal is to achieve technological advances that enable the routine use of tissue chips in safety and efficacy assessment of therapeutics. The funding opportunity is open for Phase I, Phase II, and Fast-Track grant applications, with a project duration of up to 2 years. The application due dates are February 22, 2024, February 24, 2025, and February 23, 2026. More information can be found on the grants.gov website.

    Files
    No associated files provided.
    Similar Opportunities
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through a Small Business Technology Transfer (STTR) program. The goal of this funding opportunity is to support the development of bench top, portable, automated, self-contained systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be able to automate tissue preculture and loading, system operation, perfusion systems, and cell culture conditions. It should also include in-line sensors for monitoring and sensing, as well as software for instrument control and data processing. The system should be cost-effective, mass producible, and robust. The performance of the system should be characterized and validated, and the applicant should propose quantitative metrics for evaluation. The long-term goal is to achieve technological advances that enable the routine use of tissue chips in safety and efficacy assessment of therapeutics. The funding opportunity is open for Phase I, Phase II, and Fast-Track grant applications, with a project duration of up to 2 years. The application due dates are February 22, 2024, February 24, 2025, and February 23, 2026. More information can be found on the grants.gov website.
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through their SBIR program. The goal of this funding opportunity is to support the development of benchtop, portable, automated systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be easy to use, have integrated in-line sensors, and be capable of rapid and reproducible high-throughput analysis. The system should also be capable of maintaining culture without external intervention and be remotely monitored through real-time biosensing. The fabrication procedure must be cost-effective, mass producible, and robust. The funding opportunity is open for Phase I, Phase II, Fast-Track, and Direct to Phase II grant applications. The project duration is from 2024 to 2026, with multiple application due dates. More details can be found on the grants.gov website.
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through their SBIR program. The goal of this funding opportunity is to support the development of benchtop, portable, automated systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be easy to use, have integrated sensors, and enable rapid and reproducible high-throughput analysis. The project should also focus on automation and miniaturization, with the potential for remote monitoring and real-time biosensing. The funding opportunity is open for Phase I, Phase II, Fast-Track, and Direct to Phase II grant applications. The project duration spans multiple years, with application due dates in February of each year. More information can be found on the grants.gov website.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as the production of sufficient quantities of EVs, labor-intensive isolation procedures, and non-specific isolation methodologies. The funding opportunity is open for both Phase I and Phase II (Fast track) grant applications. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The funding opportunity prioritizes IND enabling therapeutic platforms that have the potential for regulatory approval and commercialization. Applicants are encouraged to engage with regulatory authorities and address the expected commercial impact of their proposed technology platform. The application due dates are June 6, 2023, June 6, 2024, and June 6, 2025. For more information, visit the solicitation agency URL: link.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field and advance the translation of EVs into clinical applications. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. The projects should focus on large-scale GMP grade production and manufacturing challenges associated with the use of EVs as therapeutics. The application due dates are June 6th of each year from 2023 to 2025. For more information and to apply, visit the solicitation agency URL: link.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that play a role in intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as large-scale production and manufacturing of EVs for therapeutic use. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The development of IND enabling therapeutic platforms that can work towards regulatory approval and commercialization is prioritized. Applications must include project milestones and should align with the goals of the funding opportunity. The application due dates are June 6th of each year from 2023 to 2025. For more information, visit the solicitation agency URL: link.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as the production of sufficient quantities of EVs, labor-intensive isolation procedures, and non-specific isolation methodologies. The funding opportunity is open for both Phase I and Phase II (Fast track) grant applications. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The funding opportunity prioritizes IND enabling therapeutic platforms that have the potential for regulatory approval and commercialization. Applicants are encouraged to engage with the FDA Center for Biologics Evaluation and Research for regulatory guidance. The application deadline is June 6th, 2023, with subsequent deadlines in 2024 and 2025. More information can be found on the grants.gov website.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed). This grant aims to support early-career scientists and health professionals interested in transitioning to a small business to gain industry experience, receive entrepreneurial training and mentorship, and advance biomedical technology with commercial potential. The grant will provide funding for research and development efforts, as well as the employment and salaries of researchers as Program Directors/Principal Investigators overseeing the supported research project. The grant also emphasizes the importance of mentorship and entrepreneurship training, with applicants required to identify at least one mentor and develop a career development plan for the PD/PI. The grant is open for applications until April 6, 2027, and more information can be found on the grants.gov website.